Telix Pharmaceuticals Ltd has released a press release.
FDA Approves Phase II Kidney Cancer Therapy Study
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix and Radius sign Distribution Agreement for Italy
- Results Presentation and Shareholder Update 1H 2021
- App 4D and Report for Half-Year Ended 30 June 2021
- Telix and Merck pan-cancer clinical collaboration
- TLX66 in Phase II Academic Study of Pediatric Leukemia
Later from Telix Pharmaceuticals
- FDA Extends New Drug Application Review Period for Illuccix
- $12.1M R&D Tax Refund, Overseas Finding Increased to $139M
- IPAX-1 Presentation at Congress of Neurological Surgeons
- Activities Report and App 4C - September 2021 quarter
- Australian TGA Approves Illuccix for Prostate Cancer Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals